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Background: Anticoagulant therapy has been evaluated with respect to its potential use-
fulness in reducing the high mortality rates associated with severe sepsis, including
sepsis-induced disseminated intravascular coagulation (DIC) after intestinal perforation.
We examined the hypothesis that recombinant human soluble thrombomodulin (rhTM)
is effective in the treatment of patients with septic shock with sepsis-induced DIC after
laparotomy for intestinal perforation.
Methods:We performed propensity-score and instrumental variable analyses of the Japan-
ese Diagnosis Procedure Combination in-patient database, a nationwide administrative
database. The main outcome was 28-day in-hospital all-cause mortality.
Results:We categorized eligible patients (n=2202) from 622 hospitals into the rhTM group
(n=726) and control group (n=1476). Propensity-score matching created 621 matched
pairs of patients with and without rhTM.There was neither significant difference in 28-day
mortality between the two groups in the unmatched analysis (rhTM vs. control, 25.3 vs.
23.4%, respectively; difference, 1.9%; 95% CI, −1.9 to 5.7) nor in the propensity-score-
matched analysis (rhTM vs. control, 26.1 vs. 24.8%, respectively; difference, 1.3%; 95%
CI,−3.6 to 6.1).The logistic analysis showed no significant association between the use of
rhTM and the mortality in propensity-score-matched patients (OR, 1.1; 95% CI, 0.82–1.4).
The instrumental variable analyses, using the hospital rhTM-prescribing proportion as the
variable, found that receipt of rhTM was not associated with the reduction in the mortality
(risk difference, −6.7%; 95% CI, −16.4 to 3.0).
Conclusion: We found no association between administration of rhTM and 28-day mortal-
ity in mechanically ventilated patients with septic shock and concurrent DIC after intestinal
perforation.
Keywords: anticoagulants, disseminated intravascular coagulation, outcomes assessment, surgery, sepsis
INTRODUCTION
Severe sepsis is one of the most common causes of death in crit-
ically ill patients worldwide (1–4). Sepsis-induced disseminated
intravascular coagulation (DIC) results in a poor outcome and is
frequently observed among these patients (2, 5–7). Sepsis-induced
DIC is a systemic process characterized by both thrombosis and
hemorrhage (8–12). However, the treatment is generally limited
to treatment of the underlying condition and administration of
appropriate blood products (9, 11).
Recombinant human soluble thrombomodulin (rhTM; Asahi
Kasei Pharma Co., Tokyo, Japan) is used clinically for DIC treat-
ment in Japan (13, 14). Thrombomodulin is a thrombin receptor
on the endothelial cell surface and plays a vital part in the reg-
ulation of DIC (15, 16). rhTM is composed of the active extra-
cellular domain of thrombomodulin (13). Similar to membrane-
bound thrombomodulin, rhTM binds to thrombin to inactivate
coagulation, and the thrombin–rhTM complex activates protein
C to produce activated protein C (APC). APC inactivates factors
VIIIa and Va in the presence of protein S, inhibiting further throm-
bin formation (13, 16). The clinical impact of rhTM on DIC were
first examined in Japan as a phase-3 trial showing that resolution of
sepsis-induced DIC was better in patients treated with rhTM than
in those treated with heparin (13). Although there was no signifi-
cant difference in mortality between these two groups of patients
(13, 17), the clinical use of rhTM was approved in Japan by the
Japanese Ministry of Health, Labour and Welfare in 2008. Vincent
et al. (18) recently reported the results of a multinational placebo-
controlled trial (phase 2b). Although their study had inadequate
power to detect statistical significance, the 28-day mortality rate
in patients who received rhTM tended to be lower than that in
patients who received standard care alone (17.8 vs. 21.6%, respec-
tively; one-sided log-rank p= 0.17) (18). Based on these results,
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a multinational phase-3 trial of rhTM for sepsis-induced DIC
(ClinicalTrials.gov Identifier: NCT01598831) is ongoing.
Previous interventional and epidemiological studies have sug-
gested that the two major infection sites giving rise to sepsis are
the lungs and abdomen (1–3). Although the causal pathogens,
required interventions, recovery time course, severity of DIC, and
mortality rates differ between the lungs and abdomen, infection
at these two sites often results in sepsis-induced DIC (1, 6, 19,
20). Additionally, in a previous study of 6342 patients with severe
pneumonia and sepsis-induced DIC, we found no significant asso-
ciation between the use of rhTM and the 28-day mortality rate
(21). In contrast to our previous study on pneumonia (21), few
studies have examined the association between rhTM use and mor-
tality in patients with sepsis-induced DIC with a direct focus on
abdominal sepsis and the use of a large sample.
The current study evaluated whether rhTM can reduce mortal-
ity in patients with sepsis-induced DIC after intestinal perforation
confirmed by laparotomy.
MATERIALS AND METHODS
This study was approved by the institutional review board of The
University of Tokyo, which waived the requirement for informed
patient consent because of the anonymous nature of the data.
DIC DIAGNOSIS AND rhTM USE IN JAPAN
The Japanese Association for Acute Medicine (JAAM) guidelines
were published in 2006 (7). These guidelines have prompted physi-
cians to diagnose sepsis-induced DIC. The guidelines have been
widely used in most of the recent reports from Japan (8, 12, 22–24).
The JAAM DIC scoring system includes the systemic inflammatory
response syndrome score (score of 0 or 1), platelet count (score
of 0, 1, or 3), fibrin/fibrinogen degradation product levels (score
of 0 or 1), and prothrombin time ratio (score of 0, 1, or 3) (7,
25). DIC was diagnosed in patients with a total score of ≥4 (7).
The clinically approved dose of rhTM by the Japanese Ministry of
Health, Labour and Welfare is 380 U/kg/day for patients with DIC.
DATA SOURCE
For this study, we used the Japanese Diagnosis Procedure Com-
bination (DPC) inpatient database, previously described in detail
elsewhere (21, 25–27). In short, this database includes administra-
tive claims and discharge abstract data for all inpatients discharged
from more than 1000 participating hospitals, including more
than 90% of all tertiary-care hospitals in Japan (21, 25–27). The
database contains baseline patient information at admission (day
0), such as age, sex, and consciousness level [Japan Coma Scale
score: 0 (alert), 1–3 (delirious), 10–30 (somnolent), and 100–300
(comatose) points (21, 25–27)]. The diagnoses were coded with
the International Classification of Diseases 10th Revision codes
as main disease, comorbidities at admission, and post-admission
complications. Thus, the complications are clearly differentiated
from the comorbidities already present in the database. The physi-
cians in charge are obliged to record these diagnoses with reference
to the medical charts to optimize the accuracy of the recorded diag-
noses. The DPC database also includes the dosages and adminis-
tration dates of all drugs and blood products administered during
hospitalization. All interventional and surgical procedures are also
coded with the original codes. The dates with the patients’ status
on hospital admission and at discharge are recorded as well (21,
25–27).
PATIENT SELECTION
We identified mechanically ventilated patients who required vaso-
pressors and developed DIC after emergency open laparotomy for
perforation of the lower intestinal tract as recorded in the DPC
database from 1 July 2010 to 31 March 2013. The inclusion criteria
were: (1) age of ≥15 years; (2) confirmed diagnosis of perfora-
tion of the lower gastrointestinal tract at admission (coded in the
“primary diagnosis” or “comorbidities at admission” section of
the database); (3) performance of open abdominal laparotomy
excluding exploratory laparotomy on day 0 or 1; (4) presence of
septic shock, defined as use of vasopressors (noradrenaline and/or
dopamine) started on day 0 or 1; (5) performance of mechanical
ventilation after surgery on day 0 and/or 1; (6) initiation of antibi-
otic therapy on day 0 or 1; and (7) diagnosis of DIC (coded in the
“main diagnosis” or “comorbidities at admission” section of the
database). The exclusion criterion was initiation of rhTM on or
after day 2.
VARIABLES AND ENDPOINTS
In the current study, the hospital volume was defined as the num-
ber of eligible patients treated at each hospital and was subcatego-
rized into tertiles. The hospital type was categorized as academic
or non-academic.
The primary endpoint used was 28-day all-cause mortality. The
secondary endpoints were ventilator-free days (VFDs) (28) and
in-hospital mortality.
STATISTICAL ANALYSIS
We performed propensity-score matching analysis between the
rhTM and control groups based on the estimated propensity
score (29, 30). The propensity score was estimated using a logis-
tic regression model for receipt of rhTM as a function of the
following patient demographics and medication/interventions
performed on day 0 or 1: age, gender, hospital type, hospital
volume, Japan Coma Scale score, coexisting diseases, perfor-
mance of blood culture, continuous renal replacement ther-
apy/intermittent hemodialysis, catecholamine use (noradrena-
line, dopamine, and/or dobutamine), vasopressin use, steroid use,
intravenous immunoglobulin use, heparin use, use of other DIC
medications available in Japan (i.e., antithrombin, ulinastatin,
nafamostat mesilate, or gabexate mesilate), heparin use, initial
use of two or more antibiotics, each types of antibiotics used,
selective neutrophil elastase inhibitor use, albumin use, and blood
transfusion (1–3, 12, 21, 25–27, 31–34). We regarded the med-
ication/interventions administered simultaneously with rhTM as
“pre-rhTM treatments” because the critically ill status requiring
these treatments was already present at the time of admission
(21). We calculated the C-statistic to evaluate the goodness of
fit. We performed a one-to-one matched analysis using nearest-
neighbor matching based on the estimated propensity scores of
the patients. A match occurred when a patient in the rhTM group
had an estimated score within 0.2 SD of a patient in the control
group (29, 30). We defined absolute values of the standardized
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difference of more than 10% as out of balance (35), and examined
the balance of baseline variables. We compared continuous vari-
ables using t -tests and categorical variables using the chi-squared
test or Fisher’s exact test. We examined the association between
administration of rhTM and 28-day mortality using generalized
estimating equations (GEE), accounting for the paired nature of
the matched patients (36). We also performed Cox regression
analysis to assess differences in in-hospital survival rates between
patients with and without rhTM in the propensity-score-matched
groups.
Instrumental variable analysis was also carried out as a con-
firmatory analysis of the propensity-score analyses. The hospitals’
preference was used as an instrumental variable, and computed
the differences in the 28-day mortality risk between the groups
with and without rhTM, using two-stage least-squares method
adjusted for the patients’ characteristics (21, 25, 26, 37, 38). We
classified hospitals that administered rhTM to the≥75th percentile
of the eligible patients with DIC as hospitals with a preference for
rhTM and those that administered rhTM to the <75th percentile
of the eligible patients with DIC as hospitals without a preference
for rhTM (38). We estimated the risk difference and 95% confi-
dence interval (95% CI) using the ivreg2 procedure of Stata/SE
13.0 (Stata Corp., College Station, TX, USA). A partial F-test was
performed to confirm that the patterns of hospital use of rhTM is
not a weak instrument (i.e., we examined the null hypothesis that
“there was no association between patterns of hospital rhTM use
and actual rhTM use”) (37). An F-statistic of >10 indicates that
the instrument is not weak (37). The IBM SPSS version 22 (IBM,
Armonk, NY, USA) and Stata/SE 13.0 were used for all statistical
analyses.
RESULTS
PATIENTS
Of 5443 mechanically ventilated patients with septic shock after
surgically confirmed perforation of the lower intestine, 3271
patients were excluded (2963 due to DIC was not shown and
308 due to delayed start of rhTM). As depicted in Figure 1,
2202 patients (622 hospitals during the 33-month study period)
were identified as eligible for the study. These patients were
FIGURE 1 | Eligible patients undergoing propensity-score matching.
DIC, disseminated intravascular coagulation; rhTM, recombinant human
soluble thrombomodulin.
categorized into either an rhTM (n= 726) or control (n= 1476)
group and underwent propensity-score matching, from which 621
propensity-score-matched pairs were generated. The C-statistic
for the goodness of fit was 0.72 (95% CI, 0.70–0.74) in the
propensity-score model. The mean length of hospital stay was
44.8 days (95% CI, 37–52).
Baseline characteristics of the unmatched and propensity-
score-matched groups patients were shown in Tables 1 and 2.
Patients were more likely to receive rhTM if they were admitted to
an academic hospital or required renal replacement therapy, nora-
drenaline, carbapenem, antithrombin, immunoglobulin, sivelestat
sodium, or blood transfusions when the unmatched groups were
compared. After propensity-score matching were performed, all
of the baseline patient characteristics were well balanced (i.e., the
absolute value of the standardized differences<10%) between the
groups.
ENDPOINT
The overall 28-day mortality rate was 24.1% (530/2202). No
significant difference was documented in the 28-day mortality
rate between the two groups in the unmatched analysis [rhTM
vs. control, 25.3% (184/726) vs. 23.4% (346/1476), respectively;
difference, 1.9%; 95% CI, −1.9 to 5.7] or in the propensity-
score-matched analysis [rhTM vs. control, 26.1% (162/621) vs.
24.8% (154/621), respectively; difference, 1.3%; 95% CI, −3.6 to
6.1]. The logistic GEE analysis showed no significant association
between the use of rhTM and 28-day mortality in propensity-
score-matched patients (OR, 1.1; 95% CI, 0.82-1.4). In the instru-
mental variable model, the null hypothesis (i.e., no association
between hospital rhTM use and actual rhTM use) was rejected with
an F-statistic of 370 (i.e., F-statistic >10, p< 0.001). The reduc-
tion in the 28-day mortality was not significantly associated with
receipt of rhTM (risk difference,−6.7%; 95% CI,−16.4 to 3.0).
We found no significant difference in the in-hospital mortality
between the two groups of unmatched patients [rhTM vs. control,
35.7% (259/726) vs. 33.1% (489/1476), respectively; difference,
2.5%; 95% CI, −1.7 to 6.8]. Moreover, no significant difference
was found among the propensity-score-matched patients [rhTM
vs. control, 35.9% (223/621) vs. 34.3% (213/621), respectively;
difference, 3.2%; 95% CI, −3.7 to 6.9]. Cox regression analysis
showed no significant difference in in-hospital mortality between
the two groups (hazard ratio, 1.1; 95% CI, 0.88–1.3).
We found no significant difference in the number of VFDs
between the rhTM group and control groups among either
unmatched patients (14.0 vs. 14.7 days, respectively; difference,
−0.7; 95% CI,−1.7 to 0.3) or propensity-score-matched patients
(14.2 vs. 14.3 days, respectively; difference, −0.17; 95% CI, −1.0
to 1.4).
DISCUSSION
The current study suggests that there is no significant association
between rhTM use and 28-day mortality in sepsis-induced DIC
patients after laparotomy for intestinal perforation. Additionally,
no significant difference was documented in the VFDs between
the rhTM and control groups.
Anticoagulant therapy agents, such as antithrombin (39–41)
and recombinant APC (42), have been evaluated as additional
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Table 1 | Baseline patient characteristics in the unmatched and propensity-score-matched groups.
Unmatched groups Propensity-score-matched groups
Control
(n=1476)
rhTM
(n=726)
Standardized
difference, %
Control
(n=621)
rhTM
(n=621)
Standardized
difference, %
Age (years)
18–50 52 (3.5) 18 (2.5) 6.1 13 (2.1) 14 (2.3) −1.1
51–60 102 (6.9) 41 (5.6) 5.2 35 (5.6) 37 (6.0) −1.4
61–70 270 (18.3) 142 (19.6) −3.2 120 (19.3) 112 (18.0) 3.3
71–80 472 (32.0) 234 (32.2) −0.5 205 (33.0) 203 (32.7) 0.7
≥81 580 (39.3) 291 (40.1) −1.6 248 (39.9) 255 (41.1) −2.3
Sex (male) 733 (49.7) 354 (48.8) 1.8 310 (49.9) 300 (48.3) 3.2
Hospital type (academic) 363 (24.6) 235 (32.4) −17.3 200 (32.2) 187 (30.1) 4.5
Hospital volume, cases
Low, 1–7 639 (43.3) 271 (37.3) 12.2 242 (39.0) 244 (39.3) −0.7
Medium, 8–13 398 (27.0) 233 (32.1) −11.3 184 (29.6) 188 (30.3) −1.4
High, ≥14 439 (29.7) 222 (30.6) −1.8 195 (31.4) 189 (30.4) 2.1
Consciousness level (JCS score)
Alert 1003 (68.0) 466 (64.2) 8.0 407 (65.5) 406 (65.4) 0.3
Delirious 248 (16.8) 144 (19.8) −7.8 109 (17.6) 116 (18.7) −2.9
Somnolent 99 (6.7) 50 (6.9) −0.7 39 (6.3) 41 (6.6) −1.3
Comatose 126 (8.5) 66 (9.1) −2.0 66 (10.6) 58 (9.3) 4.3
Coexisting disease
Diabetes 140 (9.5) 76 (10.5) −3.3 72 (11.6) 56 (9.0) 8.5
Old myocardial infarction 20 (1.4) 12 (1.7) −2.4 10 (1.6) 10 (1.6) 0.0
Chronic obstructive pulmonary disease 44 (3.0) 18 (2.5) 3.1 17 (2.7) 17 (2.7) 0.0
Pneumonia 96 (6.5) 43 (5.9) 2.4 36 (5.8) 39 (6.3) −2.0
Liver cirrhosis 19 (1.3) 2 (0.3) 11.5 2 (0.3) 2 (0.3) 0.0
Chronic renal failure 111 (7.5) 51 (7.0) 1.9 49 (7.9) 46 (7.4) 1.8
therapies to reduce the high mortality rates associated with severe
sepsis and septic shock. Antithrombin supplementation as an
adjunct therapy in patients with sepsis-induced DIC was suggested
in the 1990s (40, 41). However, the largest randomized trial, the
KyberSept Trial (43), could not prove beneficial effects of high-
dose antithrombin therapy on mortality. Moreover, meta-analyses
of randomized trials concluded that antithrombin could not be
generally recommended for critically ill patients, including those
with severe sepsis (44). Conversely, Bernard et al. (42) suggested
the efficacy of APC on survival in patients with severe sepsis in
2001. However, APC was withdrawn from the market after the
Prospective Recombinant Human APC Worldwide Evaluation in
Severe Sepsis and Septic Shock trial documented its failure (45).
Thus, the latest Surviving Sepsis Campaign Guidelines (3), the
major international guidelines for severe sepsis, do not recom-
mend the use of antithrombin and APC for patients with severe
sepsis.
A novel anticoagulant therapy, rhTM, was developed for
patients with DIC in Japan. Several studies have investigated the
use of rhTM for sepsis-induced DIC in Japan, which is the only
country where rhTM is widely used for clinical treatment of DIC
(46–51). Several positive effects of rhTM were reported in these
studies (46–51). Additionally, Vincent et al. (18) reported that
rhTM was associated with beneficial pharmacologic effects and is
a safe intervention in critically ill patients with sepsis-induced
coagulopathy. Thus, rhTM seems to be a promising drug for
sepsis-induced DIC.
Previous studies have suggested that patients with respiratory
and/or cardiac dysfunction and evidence of DIC appear to receive
the greatest rhTM-related survival benefit (13, 17, 18, 47, 51, 52).
Therefore, in the current study, we selected patients with DIC
who required vasopressor and mechanical ventilation after emer-
gency open laparotomy for perforation of the lower intestinal tract.
The strength of the current study is the evaluation of more than
2000 patients using data throughout Japan. We used a propensity-
score matching approach to overcome the bias associated with the
measured confounding factors. After propensity-score matching,
the selected patients were well balanced with regard to baseline
characteristics, including factors with the potential to affect mor-
tality in patients with septic shock after emergency laparotomy,
as presented in Tables 1 and 2. We then attempted to construct
a “randomized experiment-like situation,” and compared groups
with similar characteristics and conditions without specifying the
relationships between measured confounding factors and out-
comes. However, we failed to confirm our hypothesis that rhTM
is associated with better survival and with reducing VFDs in the
propensity-score-matched analyses. Recent studies indicated that
rhTM acts as an anticoagulant with anti-inflammatory proper-
ties that may prevent later occurrence of multiple organ failure
(12, 49, 53). However, we could not demonstrate this effect when
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Table 2 | Medications and interventions performed on day 0 or 1 in the unmatched and propensity-score-matched groups.
Unmatched groups Propensity-score-matched groups
Control
(n=1476)
rhTM
(n=726)
Standardized
difference, %
Control
(n=621)
rhTM
(n=621)
Standardized
difference, %
Blood culture taken 635 (43.0) 377 (51.9) −17.9 317 (51.0) 310 (49.9) 2.3
Intermittent hemodialysis 237 (16.1) 126 (17.4) −3.5 107 (17.2) 104 (16.7) 1.3
Continuous renal replacement therapy 389 (26.4) 269 (37.1) −23.1 207 (33.3) 213 (34.3) −2.0
Polymyxin B hemoperfusion 403 (27.3) 226 (31.1) −8.4 182 (29.3) 186 (30.0) −1.4
Catecholamines
Dopamine use 1205 (81.6) 580 (79.9) 4.4 501 (80.7) 504 (81.2) −1.2
Noradrenaline use 993 (67.3) 557 (76.7) −21.2 464 (74.7) 462 (74.4) 0.7
Dobutamine use 210 (14.2) 148 (20.4) −16.3 100 (16.1) 114 (18.4) −6.0
Vasopressin 84 (5.7) 65 (9.0) −12.5 45 (7.2) 49 (7.9) −2.4
Initial antibiotic use
Initial use of two or more antibiotics 321 (21.7) 175 (24.1) −5.6 145 (23.3) 149 (24.0) −1.5
Pazobactam/piperacillin or sulbactam/cefoperazone sodium 117 (7.9) 70 (9.6) −6.1 52 (8.4) 60 (9.7) −4.5
First-generation cephalosporin 52 (3.5) 30 (4.1) −3.2 26 (4.2) 27 (4.3) −0.8
Second-generation cephalosporin 511 (34.6) 206 (28.4) 13.5 187 (30.1) 185 (29.8) 0.7
Third-generation cephalosporin 32 (2.2) 16 (2.2) −0.2 13 (2.1) 16 (2.6) −3.2
Fourth-generation cephalosporin 44 (3.0) 19 (2.6) 2.2 16 (2.6) 18 (2.9) −2.0
Carbapenem 971 (65.8) 531 (73.1) −16.0 446 (71.8) 439 (70.7) 2.5
Antifungal drug 29 (2.0) 20 (2.8) −5.2 14 (2.3) 15 (2.4) −1.1
Low-dose steroid 158 (10.7) 78 (10.7) −0.1 57 (9.2) 65 (10.5) −4.3
Antithrombin 622 (42.1) 439 (60.5) −37.3 350 (56.4) 347 (55.9) 1.0
Gabexate mesilate 670 (45.4) 162 (22.3) 50.3 148 (23.8) 161 (25.9) −4.8
Nafamostat mesilate 826 (56.0) 457 (62.9) −14.3 375 (60.4) 380 (61.2) −1.6
Ulinastatin 497 (33.7) 218 (30.0) 7.8 187 (30.1) 190 (30.6) −1.1
Heparin 1228 (83.2) 614 (84.6) −3.7 524 (84.4) 522 (84.1) 0.9
Immunoglobulin 740 (50.1) 419 (57.7) −15.2 345 (55.6) 347 (55.9) −0.6
Sivelestat sodium 680 (46.1) 394 (54.3) −16.5 308 (49.6) 330 (53.1) −7.1
Albumin 1222 (82.8) 630 (86.8) −11.1 529 (85.2) 534 (86.0) −2.3
Blood transfusion
Red blood cells 844 (57.2) 470 (64.7) −15.5 389 (62.6) 391 (63.0) −0.7
Fresh frozen plasma 934 (63.3) 456 (62.8) 1.0 379 (61.0) 392 (63.1) −4.3
Platelets 230 (15.6) 150 (20.7) −13.2 113 (18.2) 116 (18.7) −1.2
Volume of first blood transfusion
Overall no. of transfusions 556 (37.7) 217 (29.9) 16.5 206 (33.2) 199 (32.0) 2.4
≤500 mL 355 (24.1) 191 (26.3) −5.2 161 (25.9) 161 (25.9) 0.0
501–1000 mL 413 (28.0) 232 (32.0) −8.7 177 (28.5) 190 (30.6) −4.6
≥1001 mL 152 (10.3) 86 (11.8) −4.9 77 (12.4) 71 (11.4) 3.0
rhTM, recombinant human soluble thrombomodulin.
analyzing our data. Although the number of VFDs should have
represented the recovery of pulmonary failure in the patients in
the current study, there was no significant difference in the num-
ber of VFDs between the rhTM and control groups. These findings
are consistent with the results obtained by logistic GEE and Cox
regression analyses. Moreover, we performed also instrumental
variable analysis to address the bias of confounding factors that
were not unmeasured, and the outcome of this analysis confirmed
the robustness of the results.
The current results are consistent with those of two random-
ized trials in patients with sepsis-induced DIC (13, 18) as well as
with our previous large retrospective study that evaluated patients
with severe pneumonia with sepsis-induced DIC (21), all of which
reported non-significant mortality trends in favor of rhTM. How-
ever, we could not obtain any objective coagulation status data
from the database, including platelet counts, D-dimer or fibrino-
gen levels, and DIC scores. The scoring systems for DIC, which
exhibit various differences, were used as an inclusion criterion
and quantitatively evaluated in previous studies (13, 17, 18, 51).
Thus, we must wait for the results of an ongoing multinational
phase-3 trial (ClinicalTrials.gov Identifier: NCT01598831) before
drawing any further conclusions.
There are some limitations in the current study. First, our study
was performed retrospectively without randomization. Although
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a propensity-score method was used to adjust for measured
confounding factors, bias could inevitably exist in the form of
confounders that were not measured. For example, although
approximately 20% of patients were administered dobutamine,
the necessary information for calculating cardiac index of the
patients was not available in the database. More importantly, DIC
scores, which may indicate the severity of DIC, were also unavail-
able. We therefore performed instrumental variable analyses to
compensate for these potentially unmeasured confounders. Sec-
ond, the definition of septic shock in the current study might
be vague. Vasopressors might be used for types of shock other
than septic shock. Additionally, according to the Surviving Sep-
sis Campaign 2012 (3), septic shock is defined as “sepsis-induced
hypotension persisting despite adequate fluid resuscitation.” In
the current study, we used a surrogate definition because the term
“adequate” could not be accurately evaluated from the informa-
tion in the database. However, we believe that if the physician in
charge determined that fluid resuscitation was not “adequate” in
patients with septic shock, the next step for resuscitation must be
the use of vasopressors according to the guidelines. This explains
the definition of septic shock used in the current study. Third,
we could not determine the exact time when rhTM was adminis-
tered. We therefore could not identify if the variables used in the
propensity-score estimation were pre- or post-rhTM treatment. In
the latter case, those variables could not be used for estimating the
propensity-score (21, 54, 55). However, rhTM has a long half-life
of 20 h. Therefore, rhTM could not have affected the other inter-
ventions/medications within days 0 and 1 (12, 13, 17, 21, 56–58).
Fourth, we only evaluated mechanically ventilated patients with
concurrent septic shock and DIC after surgery for intestinal per-
foration. As a result, only a few patients in this strictly selected
population were included from each hospital. Because they were
from various institutions, they might not have been uniformly
monitored and treated. Additionally, the results cannot be gener-
alized to patients with other causes of abdominal sepsis such as
cholangitis, cholecystitis, and pancreatitis. Fifth, the selective use
of concurrent dugs affecting coagulation, including antithrombin,
gabexate mesilate, nafamostat mesilate, and heparin, may have
affected the results of the study, although the proportions of these
drugs were well balanced between the rhTM and control groups
after propensity-score matching. These drugs might be used for
the treatment of a variety of conditions in critical care other than
DIC therapy (e.g., treatment of pancreatitis or anticoagulation for
hemodialysis and/or placement of an arterial line).
CONCLUSION
We found no association between administration of rhTM and
28-day mortality in mechanically ventilated patients with septic
shock and concurrent DIC after intestinal perforation. Prospective
randomized trials are required to confirm our findings.
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